Dolutegravir/rilpivirine

Dolutegravir/rilpivirine is a medication used for the treatment of HIV/AIDS. It is a combination of two antiretroviral drugs, dolutegravir and rilpivirine. This combination is marketed under the brand name Juluca by ViiV Healthcare.

Etymology

The name "dolutegravir/rilpivirine" is derived from the names of the two active ingredients in the medication. "Dolutegravir" is a compound word formed from "dolu" (meaning "pain" in Latin) and "tegravir" (a suffix used in the names of antiretroviral drugs). "Rilpivirine" is also a compound word, with "ril" (an abbreviation for "rilpivirine") and "pivirine" (a suffix used in the names of non-nucleoside reverse transcriptase inhibitors).

Pharmacology

Dolutegravir is an integrase inhibitor, which prevents the virus from integrating its genetic material into the host cell's DNA. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), which prevents the virus from replicating its RNA into DNA.

Usage

Dolutegravir/rilpivirine is used as a complete regimen for the treatment of HIV-1 infection in adults who are virologically suppressed on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of dolutegravir/rilpivirine.

Side Effects

Common side effects of dolutegravir/rilpivirine include headache, diarrhea, and nausea. Serious side effects may include liver problems, depression, and changes in body fat distribution.

See Also

• Antiretroviral therapy
• HIV/AIDS
• Integrase inhibitor
• Non-nucleoside reverse transcriptase inhibitor

Dolutegravir/rilpivirine Resources
Latest articles Most recent articles Ongoing trials	Wikipedia